INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
TT
Corporate insider

Tanguler Tolga

EVP, Chief Commercial OfficerCIK 0001849458

EDGAR filingsOpen in network
Disclosed transactions23
Buys / sells0 / 21
Max Insider Score39
Connections with evidence2

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
TT
Tanguler TolgaDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
35.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lexeo Therapeutics, Inc.Director · Jun 29, 2026
  • Insider ofevidence
    ALNYLAM PHARMACEUTICALS, INC.EVP, Chief Commercial Officer · Jan 14, 2026
36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL
$18K
50 sh
Jan 12, 2026
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

19
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award
A—
3,800 sh
Jan 11, 2026Jan 14, 2026
traded Jan 11, 2026
+3dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence